Lifeline Biotechnologies Inc (LLBO)

[voo]

I had contact with the CEO of Cyrcadia (Rob Royea). He wrote me this:
we are entering into our final clinical validation trials by mid June (three weeks from now) at El Camino Hospital, Mt. View CA. This 173 patient trial is expected to extend to The Ohio State University and to Stanford's Canary Center for early cancer biomarker identification by July. This is exciting news for all as this trial is expected to last no more than 5 months and should show significant improvement on biopsy reduction potential for 77% of the population who today have biopsy procedures on non-cancerous tissue as a result of biopsy. The addition of the Canary Center at Stanford also affords this targeted study to prove our ability for early diagnostic findings in the earliest stages of cancer, specifically in the dense tissue population.